StreetInsider.com News Articles

Form 4 CONMED Corp For: Jul 15 Filed by: Gallagher John E

Fri, 17 Jul 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26783921.html

Form 4 CONMED Corp For: Jul 15 Filed by: Gallagher John E

Fri, 17 Jul 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26783921.html

Form 3 CONMED Corp For: Jul 15 Filed by: Gallagher John E

Fri, 17 Jul 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26783908.html

Form 3 CONMED Corp For: Jul 15 Filed by: Gallagher John E

Fri, 17 Jul 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26783908.html

Needham Comments on CONMED (CNMD) Amid Sale Rumors

Tue, 14 Jul 2026 05:44:11 -0400

Needham analyst Mike Matson reiterated a Hold rating on CONMED (NYSE: CNMD).

The analyst comments "After the market closed on 7/10/26, Bloomberg reported that CNMD has been exploring a possible sale of the company. We believe that a sale makes sense given CNMD's mid-single digit growth, strong recurring revenue composition, and depressed valuation. We expect a large premium to CNMD's discount valuation prior to the report and we believe that offers could be at a ~30-50% premium to CNMD's recent average share price ~$35 (~$46-53 per share). We think that CNMD could be attractive to larger companies but we believe that

Conmed shares jump on potential sale report

Fri, 10 Jul 2026 16:41:58 -0400

Investing.com -- Shares of CONMED Corporation rose more than 8% in after-hours trading on Friday following a Bloomberg report that the medical device company is exploring a potential sale.

The company is evaluating its options after receiving takeover interest, according to the report.

Conmed weighing sale after takeover interest - Bloomberg

Fri, 10 Jul 2026 16:36:21 -0400

Conmed weighing sale after takeover interest - Bloomberg

Fri, 10 Jul 2026 16:36:21 -0400

Conmed weighing sale after takeover interest - Bloomberg

Fri, 10 Jul 2026 16:36:21 -0400

Conmed weighing sale after takeover interest - Bloomberg

Fri, 10 Jul 2026 16:36:21 -0400

Conmed weighing sale after takeover interest - Bloomberg

BMO Capital Starts CONMED (CNMD) at Market Perform

Wed, 08 Jul 2026 16:28:16 -0400

BMO Capital initiates coverage on CONMED (NYSE: CNMD) with a Market Perform rating.

For an analyst ratings summary and ratings history on CONMED click here. For more ratings news on CONMED click here.

Shares of CONMED closed at $34.24 yesterday.

Form 4 CONMED Corp For: Jul 01 Filed by: Martin Celine Christine

Thu, 02 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260702/26729465.html

Form 4 CONMED Corp For: Jul 01 Filed by: Martin Celine Christine

Thu, 02 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260702/26729465.html

Form 4 CONMED Corp For: Jul 01 Filed by: Mirviss Jeffrey B.

Thu, 02 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729422.html

Form 4 CONMED Corp For: Jul 01 Filed by: Mirviss Jeffrey B.

Thu, 02 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729422.html

Form 3 CONMED Corp For: Jul 01 Filed by: Mirviss Jeffrey B.

Thu, 02 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26729383.html

Form 3 CONMED Corp For: Jul 01 Filed by: Mirviss Jeffrey B.

Thu, 02 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26729383.html

Form 3 CONMED Corp For: Jul 01 Filed by: Martin Celine Christine

Thu, 02 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26729355.html

Form 3 CONMED Corp For: Jul 01 Filed by: Martin Celine Christine

Thu, 02 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26729355.html

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

Thu, 02 Jul 2026 16:05:00 -0400

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

Thu, 02 Jul 2026 16:05:00 -0400

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

Thu, 02 Jul 2026 16:05:00 -0400

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

Thu, 02 Jul 2026 16:05:00 -0400

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of

BofA Securities Downgrades CONMED (CNMD) to Underperform

Mon, 29 Jun 2026 06:11:49 -0400

(Updated - June 29, 2026 6:11 AM EDT)

BofA Securities analyst Travis Steed downgraded CONMED (NYSE: CNMD) from Neutral to Underperform with a price target of $40.00.

The analyst comments "We downgrade CNMD to Underperform from Neutral as we reevaluate its relative position in our coverage. We think CNMD underperforms other medtech stocks in our coverage over a 1-year period. When dollars come back into medtech we think it’ll gravitate towards higher growth, quality, large caps that are trading a historically low valuations and single product SMIDs with high growth/large TAMs/numbers upside. CNMD is neither. We update our model. Our 2027 organic

BofA Securities Downgrades CONMED (CNMD) to Underperform

Mon, 29 Jun 2026 06:11:49 -0400

(Updated - June 29, 2026 6:11 AM EDT)

BofA Securities analyst Travis Steed downgraded CONMED (NYSE: CNMD) from Neutral to Underperform with a price target of $40.00.